N/A
Completed N=13
Effects of Clobazam on Sleep and Daytime Function in Patients With Epilepsy
Source: ClinicalTrials.gov NCT02911025 ↗Enrolled (actual)
13
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Change in Sleep (Total Sleep Time) in Patients With Epilepsy Treated With Clobazam — 493.2; 457.9 minutes
Summary
The purpose of this study is to monitor the effect of Clobazam on sleep and daytime alertness in people with Epilepsy.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Sleep (Total Sleep Time) in Patients With Epilepsy Treated With Clobazam |
493.2; 457.9 | — |
| SECONDARY Change in Sleep (Wake After Sleep Onset) in Patients With Epilepsy Treated With Clobazam |
50.2; 37.3 | — |
Eligibility Criteria
Inclusion Criteria
- adults aged 18 years or older
- diagnosis of epilepsy who are being considered for treatment with Clobazam
Exclusion Criteria
- known untreated moderate or severe sleep apnea
- major circadian rhythm disorders
Data sourced from ClinicalTrials.gov (NCT02911025). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.